Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
FBRX
Upturn stock ratingUpturn stock rating

Forte Biosciences Inc (FBRX)

Upturn stock ratingUpturn stock rating
$12.93
Last Close (24-hour delay)
Profit since last BUY12.14%
upturn advisory
SELL
SELL since 1 day
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: FBRX (1-star) is a SELL. SELL since 1 days. Profits (12.14%). Updated daily EoD!

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

4 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $48.67

1 Year Target Price $48.67

Analysts Price Target For last 52 week
$48.67Target price
Low$4.11
Current$12.93
high$28.68

Analysis of Past Performance

Type Stock
Historic Profit -34.46%
Avg. Invested days 35
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 80.65M USD
Price to earnings Ratio -
1Y Target Price 48.67
Price to earnings Ratio -
1Y Target Price 48.67
Volume (30-day avg) 4
Beta 2.86
52 Weeks Range 4.11 - 28.68
Updated Date 06/30/2025
52 Weeks Range 4.11 - 28.68
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -9.51

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -70.65%
Return on Equity (TTM) -130.27%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 34790429
Price to Sales(TTM) -
Enterprise Value 34790429
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 1.87
Shares Outstanding 6583380
Shares Floating 2900046
Shares Outstanding 6583380
Shares Floating 2900046
Percent Insiders 9.35
Percent Institutions 80.32

Analyst Ratings

Rating 2
Target Price 48.67
Buy -
Strong Buy 4
Buy -
Strong Buy 4
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Forte Biosciences Inc

stock logo

Company Overview

overview logo History and Background

Forte Biosciences, Inc. was a clinical-stage biopharmaceutical company founded in 2011. It focused on developing therapies for autoimmune diseases and inflammatory skin conditions. In September 2022, the company ceased operations after a failed Phase 2 trial of its lead drug candidate, FB-401. The company was later acquired by and became a subsidiary of Cassava Sciences Inc. in October 2022

business area logo Core Business Areas

  • Drug Development: Forte Biosciences focused on developing and testing FB-401, a live biotherapeutic for atopic dermatitis.

leadership logo Leadership and Structure

Prior to the acquisition by Cassava Sciences, Forte Biosciences was led by CEO Paul Wagner and had a typical biotech organizational structure with departments focused on research, clinical development, and business operations. It is now a subsidiary of Cassava Science. It is unclear if this continues to exist or not.

Top Products and Market Share

overview logo Key Offerings

  • FB-401: FB-401 was Forte Biosciences' lead drug candidate, a live biotherapeutic being developed for the treatment of atopic dermatitis. Market share data specific to FB-401 is unavailable because it did not receive FDA approval. Potential competitors included companies with approved treatments for atopic dermatitis, such as Sanofi (SNY) and Regeneron (REGN) with Dupixent.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive and focused on developing and commercializing new therapies. The atopic dermatitis market is a significant area of focus, with multiple companies pursuing novel treatments.

Positioning

Forte Biosciences aimed to position FB-401 as a novel, microbiome-based therapy for atopic dermatitis, differentiating itself from existing treatments. Cassava Sciences may or may not continue this path.

Total Addressable Market (TAM)

The global atopic dermatitis market was estimated at billions of USD. Forte Biosciences aimed to capture a portion of this market with FB-401, but this is unachievable since they ceased operations.

Upturn SWOT Analysis

Strengths

  • Novel microbiome-based approach
  • Focus on unmet medical needs
  • Prior clinical trial data (although ultimately unsuccessful)

Weaknesses

  • Failed Phase 2 trial of FB-401
  • Limited financial resources before acquisition
  • No approved products

Opportunities

  • Potential for future development programs under Cassava Sciences
  • Exploring other indications for FB-401
  • Partnerships and collaborations

Threats

  • Competition from established players
  • Regulatory hurdles
  • Clinical trial risks

Competitors and Market Share

competitor logo Key Competitors

  • SNY
  • REGN

Competitive Landscape

Forte Biosciences faced intense competition from established pharmaceutical companies with approved atopic dermatitis treatments.

Major Acquisitions

Cassava Sciences

  • Year: 2022
  • Acquisition Price (USD millions): 18
  • Strategic Rationale: Cassava Sciences acquired Forte Biosciences to potentially use its assets or intellectual property for their own therapeutic programs, although specific details are not publicly available.

Growth Trajectory and Initiatives

Historical Growth: Forte Biosciences experienced no revenue growth due to its status as a clinical-stage company.

Future Projections: Unclear. Future growth depends on Cassava Sciences' plans for the former Forte Biosciences assets.

Recent Initiatives: Acquisition by Cassava Sciences.

Summary

Forte Biosciences was a clinical-stage biopharmaceutical company that ceased operations after a failed clinical trial. The company was subsequently acquired by Cassava Sciences. Prior to its demise, Forte Biosciences was focused on a novel microbiome approach to treating atopic dermatitis. Its future direction and prospects now depend entirely on Cassava Sciences' strategic decisions. The failure of FB-401 severely impacted the company's value and led to its acquisition.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings
  • Industry Reports
  • Press Releases
  • Cassava Sciences website

Disclaimers:

The information provided is based on publicly available data and may not be entirely comprehensive. Market share data is an estimate and may vary. This analysis is not financial advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Forte Biosciences Inc

Exchange NASDAQ
Headquaters Dallas, TX, United States
IPO Launch date 2017-04-13
CEO, President & Chairman Dr. Paul A. Wagner Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 14
Full time employees 14

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.